Oppenheimer believes that early test results of Given Imaging's PillCam Colon 2 indicate that the product may meaningfully penetrate the market. The firm reiterates an Outperform rating on the stock. :theflyonthewall.com
News For GIVN From The Last 14 Days
Check below for free stories on GIVN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
